OPUS GENETICS INC

Company Overview

Opus Genetics is a clinical‑stage ophthalmic biotechnology company developing AAV‑based gene therapies for inherited retinal diseases (IRDs) and advancing complementary ophthalmic products. Lead programs include OPGx‑LCA5 (Phase 1/2 with encouraging adult improvements and ongoing pediatric enrollment), OPGx‑BEST1 (IND‑ready with planned Phase 1/2 data targeted Q1 2026), and a marketed topical phentolamine product (RYZUMVI) being developed in Phase 3 by licensee Viatris. The company is lean (≈18 employees), outsources manufacturing and clinical execution to CDMOs and CROs, recently completed an acquisition that materially increased R&D spend and recorded a large IPR&D charge, and relies on periodic equity financings and collaboration receipts to fund development.

Executive Compensation Practices

Compensation for Opus executives is likely skewed toward equity and long‑term, milestone‑linked incentives rather than high cash salaries, reflecting the small headcount, heavy R&D spend, and limited near‑term commercialization capability. Key pay drivers will include clinical and regulatory milestones (e.g., pediatric LCA5 readouts, BEST1 cohort data, PS Phase 3 toplines), successful partner deals (APX3330 partner, Viatris milestone/royalty timing), and capital‑raising outcomes because shareholder dilution and cash runway materially affect valuation and management incentives. Given the October 2024 acquisition and the IPR&D accounting hit, compensation plans may include retention bonuses, change‑in‑control protections, and time‑vesting equity to retain technical leadership during program ramp‑ups; option/RSU grants and warrant instruments (noted in filings) will be an important component. Expect board and compensation committees to balance retention with investor sensitivity to dilution, and to use performance conditions tied to FDA interactions (SPAs, RMAT) and clinical inflection points.

Insider Trading Considerations

Insider transactions at Opus should be monitored around discrete, high‑information events—clinical data readouts (pediatric LCA5 Q3 2025, BEST1 Q1 2026, PS toplines in 2025), FDA interactions/designations, financings (e.g., March 2025 ~$21.5M), and collaboration milestones—because those events materially move value and are frequent drivers of insider activity. The company’s reliance on equity financings and conversion events (Series A conversion, warrants) increases the likelihood of insider sales for tax/exercise or diversification purposes; watch Forms 4/144 and any option exercises or warrant exercises disclosed in filings. Regulatory and reputational constraints (Section 16 reporting, 10b5‑1 trading plans, blackout windows around clinical announcements) are especially important in biotech; insiders should avoid trading while in possession of material nonpublic clinical or partnering information, and investors should look for patterns of pre‑announcement sales or clustered trades that may signal liquidity needs or hedging.